MediWound Ltd (M8W) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MediWound Ltd (M8W) has a cash flow conversion efficiency ratio of -0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.24 Million ≈ $-3.79 Million USD) by net assets (€50.16 Million ≈ $58.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MediWound Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how MediWound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of MediWound Ltd for a breakdown of total debt and financial obligations.
MediWound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MediWound Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JCY International Bhd
KLSE:5161
|
0.086x |
|
E-World
KO:084680
|
0.002x |
|
Bukaka Teknik Utama Tbk Pt
JK:BUKK
|
0.004x |
|
Banco Hipotecario SA
BA:BHIP
|
0.381x |
|
Cabral Gold Inc
V:CBR
|
-0.169x |
|
Turk Prysmian Kablo ve Sistemleri AS
IS:PRKAB
|
0.389x |
|
Paninvest Tbk
JK:PNIN
|
0.018x |
|
PW MEDTECH GROUP DL-0001
F:PWE
|
N/A |
Annual Cash Flow Conversion Efficiency for MediWound Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of MediWound Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see M8W stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €31.15 Million ≈ $36.42 Million |
€-13.62 Million ≈ $-15.93 Million |
-0.437x | -32.03% |
| 2023-12-31 | €31.59 Million ≈ $36.94 Million |
€-10.46 Million ≈ $-12.23 Million |
-0.331x | +69.58% |
| 2022-12-31 | €10.91 Million ≈ $12.76 Million |
€-11.88 Million ≈ $-13.89 Million |
-1.089x | -155.96% |
| 2021-12-31 | €-4.58 Million ≈ $-5.36 Million |
€-8.92 Million ≈ $-10.42 Million |
1.946x | +305.23% |
| 2020-12-31 | €7.27 Million ≈ $8.50 Million |
€-6.89 Million ≈ $-8.06 Million |
-0.948x | -273.51% |
| 2019-12-31 | €15.17 Million ≈ $17.73 Million |
€8.29 Million ≈ $9.69 Million |
0.546x | +140.34% |
| 2018-12-31 | €8.97 Million ≈ $10.49 Million |
€-12.15 Million ≈ $-14.21 Million |
-1.355x | +20.80% |
| 2017-12-31 | €9.62 Million ≈ $11.25 Million |
€-16.45 Million ≈ $-19.24 Million |
-1.710x | +19.18% |
| 2016-12-31 | €7.77 Million ≈ $9.08 Million |
€-16.45 Million ≈ $-19.23 Million |
-2.116x | -- |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more